RHReginald Hill

Reginald Hill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Reginald Hill has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Alireza Sohrabi

    Department of Bioengineering, University of California, Los Angeles, CA 90095, United States

    1 shared publication
  • Bayan Mahgoub

    Lawrence J. Ellison Institute for Transformative Medicine of USC, Los Angeles, CA 90064, United States

    1 shared publication
  • Chae-Young Eun

    Lawrence J. Ellison Institute for Transformative Medicine of USC, Los Angeles, CA 90064, United States

    1 shared publication
  • Charlene DeKalb

    Lawrence J. Ellison Institute for Transformative Medicine of USC, Los Angeles, CA 90064, United States

    1 shared publication
  • Hanaa Knaneh-Monem

    Lawrence J. Ellison Institute for Transformative Medicine of USC, Los Angeles, CA 90064, United States

    1 shared publication
  • Katherine E. Richards

    Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 45556, USA

    1 shared publication

Latest Publications

  • Open Access

    Cancer-Associated Fibroblasts Confer Gemcitabine Resistance to Pancreatic Cancer Cells through PTEN-Targeting miRNAs in Exosomes

    by Katherine E. Richards, Weikun Xiao, Reginald Hill, on behalf of the USC Pancreas Research Team

    Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer-related death in the United States. Even though the poor prognosis of PDAC is often attributed to late diagnosis, patients with an early diagnosis who undergo tumor resection and adjuvant chemotherapy still show tumor recurrence, highlighting a need to develop therapies which can overcome chemoresistance. Chemoresistance has been linked to the high expression of microRNAs (miRs), such as miR-21, within tumor cells. Tumor cells can collect miRs through the uptake of miR-containing lipid extracellular vesicles called exosomes. These exosomes are secreted in high numbers from cancer-associated fibroblasts (CAFs) within the tumor microenvironment during gemcitabine treatment and can contribute to cell proliferation and chemoresistance. Here, we show a novel mechanism in which CAF-derived exosomes may promote proliferation and chemoresistance, in part, through suppression of the tumor suppressor PTEN. We identified five microRNAs: miR-21, miR-181a, miR-221, miR-222, and miR-92a, that significantly increased in number within the CAF exosomes secreted during gemcitabine treatment which target PTEN. Furthermore, we found that CAF exosomes suppressed PTEN expression in vitro and that treatment with the exosome inhibitor GW4869 blocked PTEN suppression in vivo. Collectively, these findings highlight a mechanism through which the PTEN expression loss, often seen in PDAC, may be attained and lend support to investigations into the use of exosome inhibitors as potential therapeutics to improve the effectiveness of chemotherapy.


  • Open Access

    Matrix stiffness mediates pancreatic cancer chemoresistance through induction of exosome hypersecretion in a cancer associated fibroblasts-tumor organoid biomimetic model

    by Weikun Xiao, Mahsa Pahlavanneshan, Chae-Young Eun, Xinyu Zhang, Charlene DeKalb, Bayan Mahgoub, Hanaa Knaneh-Monem, Sana Shah, Alireza Sohrabi, Stephanie K. Seidlits, et al.